Shortages, access, and cost have led to compounding GLP1s, which has created confusion and misinformation for patients and healthcare providers. Join us as we discuss this practice and delve into what you need to know as a healthcare provider.

THE GAMECHANGER: The advent of GLP1s is a true GameChanger in the health of patients with diabetes, cardiovascular diseases, and obesity, and has led to access issues for manufactured products.

 

Guests
Tenille Davis, PharmD, RPh
Chief Advocacy Officer
Alliance for Pharmacy Compounding

Scott Brunner, CAE
CEO
Alliance for Pharmacy Compounding

Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
https://a4pc.org/advocacy/educating-prescribers/

https://a4pc.org/advocacy/statements-and-other-resources/

https://a4pc.org/files/APC-Compounded-GLP-1s-Media-Brief-REVISED-March-2024.pdf

 
Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Review criteria for compounding drugs on the FDA drug shortage list.
2. Discuss the facts and misinformation surrounding compounded GLP1 medications.

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-145-H01-P
Initial release date: 04/15/2024
Expiration date: 04/15/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram